Skip to main content

Table 3 Post-ABSCT treatment, toxicities and supportive care

From: High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting

Parameters

Overall cohort

Outpatient treatment

Hospital admission

P-value

ABSCT number, n

21

14

7

/

Treatment duration

 Overall, days

21 (18–31)

21 (18–25)

22 (19–31)

0.38

 Days as outpatient

19 (8–25)

21 (18–25)

15 (8–19)

<0.01

 Days as inpatient

0 (0–18)

/

5 (2–18)

<0.01

Reason for hospital admission, n (%)

   

/

 Neutropenic fever ≥72 h

4 (19)

/

4 (57)

 

 Grade III stomatitis

2 (10)

/

2 (29)

 

 Other

1 (5)

/

1 (14)

 

Toxicities

 Stomatitis, n (%)

  I

17 (81)

13 (93)

4 (57)

 

  II

2 (10)

1 (7)

1 (14)

 

  III

2 (10)

0 (0)

2 (29)

 

 Neutropenic fever

  n, (%)

14 (67)

8 (57)

6 (86)

0.34

  No. of days with fever

3 (1–10)

2 (1–7)

4 (2–10)

0.14

 Diarrhoea, n (%)

1 (5)

1 (7)

0 (0)

1.00

 Pulmonary infection, n (%)

0 (0)

0 (0)

0 (0)

1.00

 Urinary tract infection, n (%)

1 (5)

0 (0)

1 (14)

0.33

 Positive blood cultures, n (%)

  Peripheral

4 (19)

1 (7)

3 (43)

0.09

  Central

0 (0)

0 (0)

0 (0)

1.00

 Port catheter infection, n (%)

  Suspicion of

3 (14)

0 (0)

3 (43)

0.03

  Proven

0 (0)

0 (0)

0 (0)

1.00

  Port catheter explantation

3 (14)

0 (0)

3 (43)

0.03

 SAE, n (%)

0 (0)

0 (0)

0 (0)

1.00

Support/Intervention

 Red cell transfusion, n (%)

6 (29)

3 (21)

3 (43)

0.35

 Platelet transfusion, n (%)

15 (71)

9 (64)

6 (86)

0.61

 i.v. antibiotics

  In case of neutropenic fever, n (%)

14 (67)

8 (57)

6 (86)

0.34

  At subfebrile temperature, n (%)

5 (24)

4 (29)

1 (14)

0.62

  Overall, days

7 (4–14)

7 (4–10)

8 (4–14)

0.61

  Days as outpatient

6 (1–10)

7 (4–10)

1 (0–6)

/

  Days as inpatient

5 (2–14)

/

5 (2–14)

/

  1. ABSCT autologous blood stem cell transplantation, i.v. intravenous, no. number, SAE severe adverse event. Unless otherwise indicated, data are given as medians (range)